2023 Pharmacy Pearls Diabetes Part 3

Wednesday, March 1, 2023, 8:00 AM - Wednesday, December 31, 2025, 5:00 PM, Avera CE Portal, ,

Pharmacy Pearls for Prescribers provides up-to-date information on medications, developed by a multidisciplinary group of AMG primary care physicians and pharmacists from Avera Health and Avera Health Insurance Division. An interdisciplinary group has been working to develop educational materials to meet this need. In this series we will discuss diabetes and prediabetes management related to: non-pharmacological and pharmacological considerations for prediabetes, dual activating GIP/GLP-1 receptor agonists in the management of T2D and the clinical utilization of GLP-1 agonists for A1c reduction.

Accreditation Statement:

  In support of improving patient care, Avera is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement(s)

  IPCE:  This activity was planned by and for the healthcare team, and learners will receive 1.0 IPCE credits for learning and change.

Physician:  Avera designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse: Avera designates this activity for a maximum of 1.0 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1.0 pharmacotherapeutic credits.

Pharmacy:  Avera is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Credit will be uploaded to the NABP CPE Monitor within 30 days after the activity completion.  Per ACPE rules, Avera does not have access nor the ability to upload credits requested after the evaluation closes.  It is the responsibility of the pharmacist to provide the correct information (NABP ID and DOB (MMDD) in order to receive credit.

1. Discuss factors that predispose patients to prediabetes
2. Identify non-pharmacological considerations to prevent the progression from prediabetes to Type 2 Diabetes (T2D)
3. Identify pharmacological considerations when prediabetes progresses to Type 2 Diabetes (T2D)
4. Review dual activating GIP/GLP-1 receptor agonists in the management of Type 2 Diabetes (T2D)
5. Describe the clinical utilization of GLP-1 agonists for A1c Reduction.
6. Describe how a multidisciplinary approach can contribute to continuous and reliable patient care

There is no cost for this educational activity.

Mitigation of Relevant Financial Relationships

Avera adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.

Individuals in a position to control the content of this CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible companies. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships listed below have been mitigated prior to the commencement of the activity.